Signaling pathways activated by daunorubicin

Blood

Volumn 98, Issue 4, 2001, Pages 913-924

  Laurent, Guy ^a,b   Jaffrézou, Jean Pierre ^a,b  

^a INSTITUT CLAUDIUS REGAUD   (France)

^b CHU PURPAN   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACYLSPHINGOSINE DEACYLASE; ANTHRACYCLINE DERIVATIVE; CASPASE; CELL RECEPTOR; CERAMIDE; CYCLIN DEPENDENT KINASE; DAUNORUBICIN; DIACYLGLYCEROL; FAS ANTIGEN; FAS LIGAND; GLUCOSYLCERAMIDE; HEMOPOIETIC GROWTH FACTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIPID; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLCHOLINE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHORYLCHOLINE; PROTEIN KINASE C; PROTEIN P21; PROTEIN P53; REACTIVE OXYGEN METABOLITE; SCLEROPROTEIN; SPHINGOMYELIN; SPHINGOMYELIN PHOSPHODIESTERASE; SPHINGOSINE 1 PHOSPHATE; STRESS ACTIVATED PROTEIN KINASE; TRANSCRIPTION FACTOR AP 1; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG;

ACUTE NONLYMPHOCYTIC LEUKEMIA; CANCER RESEARCH; CLINICAL RESEARCH; DRUG CYTOTOXICITY; DRUG RESEARCH; ENZYME ACTIVATION; EXTRACELLULAR MATRIX; HUMAN; LIPID METABOLISM; ONCOGENE; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR GENE;

EID: 0035883083     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V98.4.913     Document Type: Review

References (197)

1. Myers CE, Chabner BA. Antracyclines. In: Chabner BA, Collins JM, eds. Cancer Chemotherapy. Principles and Practice. Philadelphia, PA: JB Lippincott; 1990:356-381.
2. Tritton TR. Cell surface actions of adriamycin. Pharmac Ther. 1991;49:293-309.
3. Potmesil M, Kirschenbaum J, Israel M, Levin M, Khetarpal VK, Silber R. Relationship of adriamycin concentrations to the DNA lesions induced in hypoxic and euoxic L1210 cells. Cancer Res. 1983;43:3528-3533.
4. Ross WE, Glaubiger K, Kohn KW. Qualitative and quantitative aspects of intercalator-induced DNA strand breaks. Biochim Biophys Acta. 1979;5629:41-50.
5. Zwelling LA, Kerrigan D, Michaels S. Cytotoxicity and DNA strand breaks by 5-iminodaunorubicin in mouse leukemia L1210 cells: comparison with adriamycin and 4′-(9-acridinylamino)-methanesulfon-m-aniside. Cancer Res. 1982;42:2687-2691.
6. Quillet-Mary A, Mansat V, Duchayne E, et al. Daunorubicin-induced internucleosomal DNA fragmentation in acute myeloid cell lines. Leukemia. 1996;10:417-425.
7. Bailly JD, Muller C, Jaffrézou JP, et al. Lack of correlation between expression and function of P-glycoprotein in acute myeloid leukemic cells. Leukemia. 1995;9:799-807.
8. Obeid LM, Linardic CM, Karolak LA, Hannun YA. Programmed cell death induced by ceramide. Science. 1993;259:1769-1771.
9. Haimovitz-Friedmann A, Kan CC, Ehleiter D, et al. Ionizing radiation acts on cellular membranes to generate ceramide and initiate apoptosis. J Exp Med. 1994;180:525-535.
10. Jaffrézou JP, Levade T, Bettaieb A, et al. Daunorubicin induced apoptosis: triggering of ceramide generation through sphingomyelin hydrolysis. EMBO J. 1996;15:2417-2424.
11. Bezombes C, Ségui B, Cuvillier O, et al. Lysosomal sphingomyelinase is not solicited for apoptosis signaling. FASEB J. 2001;15:297-299.
12. Bose R, Verheij M, Haimovitz-Friedman A, Scotto K, Fuks Z, Kolesnick R. Ceramide synthase mediates daunorubicin-induced apoptosis: an alternative mechanism for generating death signals. Cell. 1995;82:405-414.
13. Xu J, Chen-Hsiung Y, Chen S, et al. Involvement of de novo ceramide biosynthesis in tumor necrosis factor-α/cycloheximide-induced cerebral endothelial cell death. J Biol Chem. 1998;273:16521-16526.
14. Bourteefe S, Hauber A, Döppler H, et al. Tumor necrosis factor induces ceramide oscillations and negatively controls sphingolipid synthases by caspases in apoptotic Kym-1 cells. J Biol Chem. 1998;273:31245-31251.
15. Jaffrézou JP, Maestre N, Mansat V, Bezombes C, Levade T, Laurent G. Positive feedback control sphingomyelinase activity by ceramide. FASEB J. 1998;12:999-1006.
16. Verheij M, Bose R, Lin XH, et al. Requirement for ceramide-initiated SAPK/JNK signalling in stress-induced apoptosis. Nature. 1996;380:75-79.
17. Sawa H, Okazaki T, Yamamoto H, et al. Requirement of AP-1 for ceramide-induced apoptosis in human leukemia HL-60 cells. J Biol Chem. 1995;270:27326-27331.
18. Lange-Carter CA, Johnson GL. Ras-dependent growth factor regulation of MEK kinase in PC12 cells. Science. 1994;265:1458-1461.
19. Johnson NL, Gardner AM, Diener KM, et al. Signal transduction pathways regulated by mitogen-activated/extracellular response kinase kinase kinase induce cell death. J Biol Chem. 1996;271:3229-3237.
20. Ichijo H, Nishida E, Irie K, et al. Induction of apoptosis by ASK1, a mammalian MAPKKK that activates SAPK/JNK and p38 signalling pathways. Science. 1997;275:90-94.
21. Osborn MT, Chambers TC. Role of the stress-activated/c-Jun NH2-terminal protein kinase pathway in the cellular response to adriamycin and other chemotherapeutic drugs. J Biol Chem. 1996;271:30950-30955.
22. Yu R, Shtil AA, Tan TH, Roninson IB, Kong AN. Adriamycin activates c-jun N-terminal kinase in human leukemia cells: a relevance to apoptosis. Cancer Lett. 1996;107:73-81.
23. Mansat-De Mas V, Bezombes C, Quillet-Mary A, et al. Implication of radical oxygen species in ceramide generation, c-Jun N-terminal kinase activation and apoptosis induced by daunorubicin. Mol Pharmacol. 1999;56:867-874.
24. Devary Y, Gottlieb RA, Smeal T, Karin M. The mammalian ultraviolet response is triggered by activation of Src tyrosine kinases. Cell. 1992;71:1081-1091.
25. Kharbanda S, Ren R, Pandley P, et al. Activation of the c-Abl tyrosine kinase in the stress response to DNA-damaging agents. Nature. 1995;376:785-788.
26. Shafman TD, Saleem A, Kyriakis J, Weichselbaum R, Kharbanda S, Kufe DW. Defective induction of stress-activated protein kinase activity in ataxia-telangiectasia cells exposed to ionizing radiation. Cancer Res. 1995;55:3242-3245.
27. Chen Y-R, Meyer CF, Tan T-H. Persistant activation of c-Jun N-terminal kinase 1 (JNK1) in γ radiation-induced apoptosis. J Biol Chem. 1996;27:631-634.
28. Kharbanda S, Pandey P, Ren R, Mayer BJ, Zon L, Kufe D. c-Abl activation regulates induction of the SEK1/stress-activated protein kinase pathway in the cellular response to 1-β-D-arabino-furanosylcytosine. J Biol Chem. 1995;270:30278-30281.
29. Amato SF, Swart JM, Berg M, Wanebo HJ, Mehta SR, Chiles TC. Transient stimulation of the c-Jun-NH2-terminal kinase/activator protein 1 pathway and inhibition of extracellular signal-regulated kinase are early effects in paclitaxel-mediated apoptosis in human B lymphoblasts. Cancer Res. 1998;58:241-247.
30. Lee L-F, Li G, Templeton DJ, Ting JP. Paclitaxel (Taxol)-induced gene expression and cell death are both mediated by the activation of c-Jun NH2-terminal kinase (JNK/SAPK). J Biol Chem. 1998;273:28253-28260.
31. Kyriakis JM, Avruch J. Sounding the alarm: protein kinase cascades activated by stress and inflammation. J Biol Chem. 1996;271:24313-24316.
32. Mansat V, Laurent G, Levade T, Bettaïeb A, Jaffrezou JP. The protein kinase C activators phorbol esters and phosphatidylserine inhibit neutral sphingomyelinase activation, ceramide generation, and apoptosis triggered by daunorubicin. Cancer Res. 1997;57:5300-5304.
33. Chmura SJ, Nodzenski E, Weichselbaum RR, Quintans J. Protein kinase C inhibition induces apoptosis and ceramide production through activation of a neutral sphingomyelinase. Cancer Res. 1996;56:2711-2714.
34. Linardic CM, Hannun YA. Identification of a distinct pool of sphingomyelin involved in the sphingomyelin cycle. J Biol Chem. 1994;269:23530-23537.
35. Bailly JD, Skladanowski A, Bettaieb A, Mansat V, Larsen AK, Laurent G. Natural resistance of acute myeloid leukemia cell lines to mitoxantrone is associated with lack of apoptosis. Leukemia. 1997;11:1523-1532.
36. Bettaieb A, Record M, Cöe MG, et al. Opposite effects of tumor necrosis factor α on the sphingomyelin-ceramide pathway in two myeloid leukemia cell lines: role of transverse sphingomyelin distribution in the plasma membrane. Blood. 1996;88:1465-1472.
37. Bezombes C, Maestre N, Laurent G, Levade T, Bettaieb A, Jaffrézou JP. Restoration of TNF-α-induced ceramide generation in resistant human leukemia KG1a cells by the P-glycoprotein blocker PSC833. FASEB J. 1998;12:101-109.
38. Tepper AD, Ruurs P, Wiedmer T, Sims PJ, Borst J, van Blitterswijk WJ. Sphingomyelin hydrolysis to ceramide during the execution phase of apoptosis results from phospholipid scrambling and alters cell-surface morphology. J Cell Biol. 2000;150:155-164.
39. Luberto C, Hannun YA. Sphingomyelin synthase, a potential regulator of intracellular levels of ceramide and diacylglycerol during SV40 transformation: does sphingomyelin synthase account for the putative phosphatidylcholine-specific phospholipase C? J Biol Chem. 1998;273:14550-14559.
40. Hampton RY, Morand OH. Sphingomyelin synthase and PKC activation. Science. 1989;246:1050.
41. Ségui B, Bezombes C, Uro-Costes E, et al. Stress-induced apoptosis is not mediated by endolysosomal ceramide. FASEB J. 2000;14:36-47.
42. Coroneos E, Martinez M, McKenna S, Kester M. Differential regulation of sphingomyelinase and ceramidase activities by growth factors and cytokines: implications for cellular proliferation and differentiation. J Biol Chem. 1995;270:23305-23309.
43. Cuvillier O, Pirianov G, Kleuser B, et al. Suppression of ceramide-mediated programmed cell death by sphingosine-1-phosphate. Nature. 1996;381:800-803.
44. Cuvillier O, Rosenthal DS, Smulson ME, Spiegel S. Sphingosine 1-phosphate inhibits activation of caspases that cleave poly(ADP-ribose) polymerase and lamins during Fas- and ceramide-mediated apoptosis in Jurkat T lymphocytes. J Biol Chem. 1998;273:2910-2916.
45. Kleuser B, Cuvillier O, Spiegel S. 1α,25-dihydroxyvitamin D3 inhibits programmed cell death in HL-60 cells by activation of sphingosine kinase. Cancer Res. 1998;58:1817-1824.
46. Perez GI, Knudson CM, Leykin L, Korsmeyer SJ, Tilly JL. Apoptosis-associated signaling pathways are required for chemotherapy-mediated female germ cell destruction. Nat Med. 1997;3:1228-1232.
47. Shayman JA, Deshmukh GD, Mahdiyoun S, et al. Modulation of renal epithelial cell growth by glucosylceramide: association with protein kinase C, sphingosine, and diacylglycerol. J Biol Chem. 1991;266:22968-22974.
48. Abe A, Radin NS, Shayman JA, et al. Structural and stereochemical studies of potent inhibitors of glucosylceramide synthase and tumor cell growth. J Lipid Res. 1995;36:611-621.
49. Rani CS, Abe A, Chang Y, et al. Cell cycle arrest induced by an inhibitor of glucosylceramide synthase: correlation with cyclin-dependent kinases. J Biol Chem. 1995;270:2859-2867.
50. Liu YY, Han TY, Giulano AE, Cabot MC. Expression of glucosylceramide synthase, converting ceramide to glucosylceramide, confers adriamycin resistance in human breast cancer cells. J Biol Chem. 1999;274:1140-1146.
51. Lavie Y, Cao H-T, Volner A, et al. Agents that reverse multidrug resistance, tamoxifen, verapamil, and cyclosporin A, block glycosphingolipid metabolism by inhibiting ceramide glycosylation in human cancer cells. J Biol Chem. 1997;272:1682-1687.
52. Liu Y-Y, Han T-Y, Giulano AE, Hansen N, Cabot MC. Uncoupling ceramide glycosylation by transfection of glucosylceramide synthase antisense reverses adriamycin resistance. J Biol Chem. 2000;275:7138-7143.
53. Come MG, Bettaieb A, Skladanowski A, Larsen AK, Laurent G. Alteration of the daunorubicin-triggered sphingomyelin-ceramide pathway and apoptosis in MDR cells: influence of drug transport abnormalities. Int J Cancer. 1999;81:580-587.
54. Lavie Y, Cao H-t, Bursten SL, Giulano AE, Cabot MC. Accumulation of glucosylceramide in multi-drug-resistant cancer cells. J Biol Chem. 1996;271:19530-19536.
55. Lucci A, Cho WI, Han TY, Giulano AE, Cabot MC. Glucosylceramide: a marker for multiple-drug resistant cancers. Anticancer Res. 1998;18:475-480.
56. Lucci A, Han TY, Liu YY, Giuliano AE, Cabot MC. Modification of ceramide metabolism increases cancer cell sensitivity to cytotoxics. Int J Oncol. 1999;15:541-546.
57. Lucci A, Han TY, Liu YY, Giuliano AE, Cabot MC. Multidrug resistance modulators and doxorubicin synergize to elevate ceramide levels and elicit apoptosis in drug-resistant cancer cells. Cancer. 1999;86:299-310.
58. Cabot MC, Giulano AE, Han T-Y, Liu Y-Y. SDPSC 833, the cyclosporin A analogue and multi-drug resistance modulator, activates ceramide synthesis and increases vinblastine sensitivity in drug-sensitive and drug-resistant cancer cells. Cancer Res. 1999;59:880-885.
59. Veldman RJ, Sietsma H, Klappa K, Hoeckstr D, Kok JW. Inhibition of P-glycoprotein activity and chemosensitization of multidrug-resistant ovarian carcinoma 2780 AD cells by dexanoyl glucosylceramide. Biochem Res Commun. 1999;266:492-496.
60. Allouche M, Bettaïeb A, Vindis C, Rousse A, Grignon C, Laurent G. Influence of Bcl-2 overexpression on the ceramide pathway in daunorubicin-induced apoptosis of leukemic cells. Oncogene. 1997;14:1837-1845.
61. Martin SJ, Takayama S, McGahon A, et al. Inhibition of ceramide-induced apoptosis by Bcl-2. Cell Death Differ. 1995;2:253-257.
62. Jarvis WDJ, Fornari FA, Browning JL, Gewirtz DA, Kolesnick RN, Grant SG. Attenuation of ceramide-induced apoptosis by diglyceride in human myeloid leukemia cells. J Biol Chem. 1994;269:31685-31692.
63. Jarvis WD, Fornari FA, Traylor RS, et al. Induction of apoptosis and potentiation of ceramide-mediated cytotoxicity by sphingoid bases in human myeloid leukemia cells. J Biol Chem. 1996;271:8275-8284.
64. Miyajima A, Mui AL-F, Ogorochi T, Sakamaki K. Receptors for granulo-macrophage colony-stimulating factor, interleukin-3, and interleukin-5. Blood. 1993;82:1960-1974.
65. Lotem J, Sachs L. Hematopoietic cytokines inhibit apoptosis induced by transforming growth factor β1 and cancer chemotherapy compounds in myeloid leukemic cells. Blood. 1992;80:1750-1757.
66. Kaplinski C, Lotem J, Sachs L. Protection of human myeloid leukemic cells against doxorubicin-induced apoptosis by granulocyte-macrophage colony-stimulating factor and interleukin 3. Leukemia. 1996;10:460-465.
67. Laredo J, Huyn A, Muller C, et al. Effect of the protein kinase C inhibitor staurosporine on chemosensitivity to daunorubicin of normal and leukemic fresh myeloid cells. Blood. 1994;84:229-237.
68. Plo I, Lautier D, Casteran N, Dubreuil P, Arock M, Laurent G. Kit activation inhibits daunorubicin-induced sphingomyelin cycle and apoptosis through a phospholipase Cγ and protein kinase C-dependent mechanism. Hematolgie. 2001;7:25a.
69. Sinha BK, Mimmaugh EG. Free radicals and anti-cancer drug resistance: oxygen free radicals in the mechanisms of drug cytotoxicity and resistance by certain tumors. Free Radicals Biol Med. 1990;8:567-581.
70. Pedersen JZ, Marcocci L, Rossi L, Mavelli I, Rotilio G. Generation of daunomycin radicals on the outer side of the erythrocyte membrane. Biochem Pharmacol. 1990;168:240-247.
71. Gutteridge JM. Lipid peroxidation and possible hydroxyl radical formation stimulated by the self-reduction of a doxorubicin-iron (III) complex. Biochem Pharmacol. 1984;33:1725-1728.
72. Liu B, Andrieu-Abadie N, Levade T, Zhang P, Obeid LM, Hannun YA. Glutathione regulation of neutral sphingomyelinase in tumor necrosis factor-α-induced cell death. J Biol Chem. 1998;273:11313-11320.
73. Singh I, Pahan K, Khan M, Singh A. Cytokine-mediated induction of ceramide production is redox-sensitive. J Biol Chem. 1998;273:20354-20362.
74. Garcia-Ruiz C, Colell A, Mari M, Morales A, Fernandez-Checa JC. Direct effect of ceramide on the mitochondrial electron transport chain leads to generation of reactive species. J Biol Chem. 1997;272:11369-11377.
75. Quillet-Mary A, Jaffrézou JP, Mansat V, Bordier C, Naval J, Laurent G. Implication of mitochondrial hydrogen peroxide generation in ceramide-induced apoptosis. J Biol Chem. 1997;272:21388-21395.
76. Verhaegen S, McGowan AJ, Brophy AR, Fernandes RS, Cotter TG. Inhibition of apoptosis by antioxidants in the human HL-60 leukaemia cell line. Biochem Pharmacol. 1995;50:1021-1029.
77. Fiorani M, Cantoni O, Tasinato A, Boscoboinik D, Azzi A. Hydrogen peroxide- and fetal bovine serum-induced DNA synthesis in vascular smooth muscle cells: positive and negative regulation by protein kinase C isoforms. Biochim Biophys Acta. 1995;1269:98-104.
78. Ohmori S, Shirai Y, Sakai N, et al. Three distinct mechanisms for translocation and activation of the delta subspecies of protein kinase C. Mol Cell Biol. 1998;18:5263-5271.
79. Chen CC, Liau CS, Lee YT. Tumor necrosis factor-alpha, platelet-activating factor, and hydrogen peroxide activate protein kinase C subtypes alpha and epsilon in human saphenous vein endothelial cells. J Cardiovasc Pharmacol. 1996;28:240-244.
80. Devary Y, Rosette C, DiDonato JA, Karin M. NF-κB activation by ultraviolet light not dependent on a nuclear signal. Science. 1993;261:1442-1445.
81. Kasid U, Suy S, Dent P, Ray S, Whiteside TL, Sturgill TW. Activation of Raf by ionizing radiation. Nature. 1996;382:813-816.
82. Suy S, Anderson WB, Dent P, Chang E, Kasid U. Association of Grb2 with Sos and Ras with Raf-1 upon gamma irradiation of breast cancer cells. Oncogene. 1997;15:53-61.
83. 2. Proc Natl Acad Sci U S A. 1997;94:11233-11237.
84. Aikawa AR, Komuro I, Yamazaki T, et al. Oxidative stress activates extracellular signal-regulated kinases through Src and Ras in cultured cardiac myocytes of neonatal rats. J Clin Invest. 1997;100:1813-1821.
85. 2 in swiss 3T3 fibroblasts. J Biol Chem. 1998;273:29986-29994.
86. Russo T, Zambrano N, Esposito F, et al. A p53-independent pathway for activation of WAF1/CIP1 expression following oxidative stress. J Biol Chem. 1995;270:29386-29391.
87. 2: role in cell survival following oxidant injury. J Biol Chem. 1996;271:4138-4142.
88. Baeuerle PA, Henkel T. Function and activation of NF-κB in the immune system. Annu Rev Immunol. 1994;12:141-179.
89. Wang C-Y, Mayo MW, Baldwin AS. TNF-α and cancer therapy-induced apoptosis: potentiation by inhibition of NF-κB. Science. 1996;274:784-787.
90. Posada J, Vichi P, Tritton TR. Protein kinase C in adriamycin action and resistance in mouse sarcoma 180 cells. Cancer Res. 1989;49:6634-6639.
91. Bettaieb A, Plo I, Mansat-De Mas V, et al. Daunorubicin- and mitoxantrone-triggered phosphatidylcholine hydrolysis: implication in drug-induced ceramide generation. Mol Pharmacol. 1999;55:118-125.
92. Kolesnick R, Fuks Z. Ceramide: a signal for apoptosis or mitogenesis? J Exp Med. 1995;181:1949-1952.
93. Bjorkoy G, Overvathn A, Diaz-Meco MT, Moscat J, Johansen T. Evidence for a bifurcation of the mitogenic signaling pathway activated by Ras and phosphatidylcholine-hydrolyzing phospholipase C. J Biol Chem. 1995;270:21299-21306.
94. Van Dijk MCM, Hilkmann H, van Blitterswijk WJ. Platelet-derived growth factor activation of mitogen-activated protein kinase depends on the sequential activation of phosphatidylcholine-specific phospholipase C, protein kinase C-δ and Raf-1. Biochem J. 1997;325:303-307.
95. Xia Z, Dickens M, Raingeaud J, Davis RJ, Greenberg ME. Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science. 1995;270:1326-1331.
96. Gokhale PC, Soldatenkov V, Wang FH, Rahman A, Dritschilo A, Kasid U. Antisense raf oligodeoxyribonucleotide is protected by liposomal encapsulation and inhibits Raf-1 protein expression in vitro and in vivo: implication for gene therapy of radioresistant cancer. Gene Ther. 1997;4:1289-1299.
97. Pirollo KF, Hao Z, Rait A, Ho CW, Chang EH. Evidence supporting a signal transduction pathway leading to the radiation-resistant phenotype in human tumor cells. Biochem Biophys Res Commun. 1997;230:196-201.
98. Berra E, Diaz-Meco MT, Dominguez I, et al. Protein kinase C δ isoform is critical for mitogenic signal transduction. Cell. 1993;74:555-563.
99. Berra E, Municio MM, Sanz L, Frutos S, Diaz-Meco MT, Moscat J. Positioning atypical PKC isoforms in the UV-induced apoptotic signaling cascade. Mol Cell Biol. 1997;17:4346-4354.
100. Murray NR, Fields AP. Atypical protein kinase C protects human leukemia cells against drug-induced apoptosis. J Biol Chem. 1997;272:27521-27524.
101. Diaz-Laviada I, Larrodera P, Diaz-Meco MT, et al. Evidence for a role of phosphatidylcholine-hydrolysing phospholipase C in the regulation of protein kinase C by ras and src oncogenes. EMBO J. 1990;9:3907-3912.
102. Rao P, Kitamura T, Miyajima A, Mufson RA. Human IL-3 receptor signaling: rapid induction of phosphatidylcholine hydrolysis is independent of protein kinase C but dependent on tyrosine phosphorylation in transfected NIH 3T3 cells. J Immunol. 1995;154:1664-1674.
103. Rao P, Mufson RA. Human interleukin-3 stimulates a phosphatidylcholine specific phospholipase C and protein kinase C translocation. Cancer Res. 1994;54:777-781.
104. Machleidt T, Krämer B, Adam D, et al. Function of the p55 tumor necrosis factor receptor "death domain" mediated by phosphatidylcholine-specific phospholipase C. J Exp Med. 1996;184:725-733.
105. Franke TF, Kaplan DR, Cantley LC, Toker A. Direct regulation of the Akt proto-oncogene product by phosphatidylinositol-3,4-biphophate. Science. 1997;275:665-668.
106. Franke TF, Kaplan DR, Cantley LC. PI3K: downstream AKTion blocks apoptosis. Cell. 1997;88:435-437.
107. Toker A, Meyer M, Reddy KK, et al. Activation of protein kinase C family members by the novel polyphosphoinositides Ptdlns-3,4-P2 and Ptdlns-3,4,5-P3. J Biol Chem. 1994;269:32358-32367.
108. Nakanishi H, Brewer KA, Exton JH. Activation of the ζ isozyme of protein kinase C by phosphatidyiinositol 3,4,5-triphosphate. J Biol Chem. 1993;268:13-16.
109. Bae YS, Cantley LG, Chen C-S, Kim S-R, Kwon K-S, Rhee SG. Activation of phospholipase C-γ by phosphatidylinositol 3,4,5-triphosphate. J Biol Chem. 1998;273:4465-4469.
110. Price BD, Youmell MB. The phosphatidylinositol 3-kinase inhibitor wortmannin sensitizes murine fibroblasts and human tumor cells to radiation and blocks induction of p53 following DNA damage. Cancer Res. 1996;56:246-250.
111. Kulik G, Klippel A, Weber MJ. Antiapoptotic signalling by the insulin-like growth factor I receptor, phosphatidylinositol 3-kinase, and Akt. Mol Cell Biol. 1997;17:1595-1606.
112. Plo I, Bettaieb A, Payrastre B, et al. Phosphoinositide 3-kinase/Akt-mediated survival pathway is activated by daunorubicin in human acute myeloid leukemia cell lines. FEBS Lett. 1999;452:150-154.
113. O'Gorman DM, Mc Kenna SL, McGahon AJ, Knox KA, Cotter TG. Sensitization of HL60 human apoptosis by inhibition of PI3-kinase survival signals. Leukemia. 2000;14:602-611.
114. Rodriguez-Viciana P, Warne PH, Khwaja A, et al. Role of phosphoinositide 3-OH kinase in cell transformation and control of the actin cytoskeleton by Ras. Cell. 1997;89:457-467.
115. Varticovski L, Daley GQ, Jackson P, Baltimore D, Cantley LC. Activation of phosphatidylinositol 3-kinase in cells expressing abl oncogene variants. Mol Cell Biol. 1991;11:1107-1113.
116. Skorski T, Bellacosa A, Nieborovska-Skorska M, et al. Transformation of hematopoietic cells by BCR/ABL requires activation of a PI-3k/Akt-dependent pathway. EMBO J. 1997;16:6151-6161.
117. Skorski T, Kanakaraj P, Nieborovska-Skorska M, et al. Phosphatidylinositol-3 kinase activity is regulated by BCR/ABL and is required for the growth of Philadelphia chromosome-positive cells. Blood. 1995;86:726-736.
118. Casteran N, Rottapel R, Beslu N, Lecocq E, Birnbaum D, Dubreuil P. Analysis of the mitogenic pathway of the FLT3 receptor and characterization in its C terminal region of a specific binding site for the PI3-kinase. Cell Mol Biol. 1994;40:443-456.
119. Del Peso L, Gonzales-Garcia M, Page C, Herrera R, Nunez G. Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt. Science. 1997;278:687-689.
120. Kennedy SG, Wagner AJ, Conzen SD, et al. The PI 3-kinase/Akt signaling pathway delivers an apoptotic signal. Genes Dev. 1997;11:701-713.
121. Cardone MH, Roy N, Stennicke HR, et al. Regulation of cell death protease caspase-9 by phosphorylation. Science. 1998;282:1318-1321.
122. Zhou H, Summers SA, Birbaum MJ, Pittman RN. Inhibition of Akt kinase by cell-permeable ceramide and its implication for ceramide-induced apoptosis. J Biol Chem. 1998;273:16568-16575.
123. Piret B, Pirette J. Topoisimerase poisons activate the transcription factor NF-kappaB in ACH-2 and CEM cells. Nucleic Acids Res. 1996;24:4242-4248.
124. Boland MP, Foster SJ, O'Neill LAJ. Daunorubicin activates NFκB and induces κB-dependent gene expression in HL-60 promyelocytic and Jurkat T lymphoma cells. J Biol Chem. 1997;272:12952-12960.
125. Das KC, White CW. Activation of NF-κB by antineoplastic agents: role of protein kinase C. J Biol Chem. 1997;272:14914-14920.
126. Hellin A-C, Calmant P, Gielin J, Bours V, Merville M-P. Nuclear factor-κB-dependent regulation of p53 gene expression induced by daunomycin genotoxic drug. Oncogene. 1998;16:1187-1195.
127. Bentires-Alj M, Hellin A-C, Ameyar M, Chouaib S, Merville M-P, Bours V. Stable inhibition of nuclear factor kB in cancer cells does not increase sensitivity to cytotoxic drugs. Cancer Res. 1999;59:811-815.
128. Brach MA, Kharbanda SM, Herrmann F, Kufe DW. Activation of the transcription factor kB in human KG-1 myeloid leukemia cells treated with 1-β-D-Arabinofuranosylcytosine. Mol Pharmacol. 1991;41:60-63.
129. Slater AF, Kimland M, Jiang SA, Orrenius S. Constitutive nuclear NF kappa B/rel DNA-binding activity of rat thymocytes is increased by stimuli that promote apoptosis, but not inhibited by pyrrolidine dithiocarbamate. Biochem J. 1995;312:833-838.
130. Schutze SK, Potthoff T, Machleidt D, Berkovic K, Wiegmann K, Kronke M. TNF activates NF-κB by phosphatidylcholine-specific phospholipase C-induced "acidic" sphingomyelin breakdown. Cell. 1992;71:765-771.
131. Mansat V, Bettaieb A, Levade T, Laurent G, Jaffrézou JP. Serine-protease inhibitors block neutral sphingomyelinase activation, ceramide generation and apoptosis triggered by daunorubicin. FASEB J. 1997;11:695-702.
132. Johns LD, Sarr T, Ranges GE. Inhibition of ceramide pathway does not affect ability of TN F-α to activate nuclear factor-κB. J Immunol. 1994;152:5877-5882.
133. Betts JC, Agranoff AB, Nabel GJ, Shayman JA. Dissociation of endogenous cellular ceramide from N F-κB activation. J Biol Chem. 1994;269:8455-8458.
134. Lallena MJ, Diaz-Meco MT, Bren G, Paya CV, Moscat J. Activation of IkappaB kinase beta by protein kinase C isoforms. Mol Cell Biol. 1999;19:2180-2188.
135. Nidai Ozes O, Mayo LD, Gustin JA, Pfeffer SR, Pfeffer LM, Donner DB. NF-κB activation by tumour necrosis factor requires the Akt serine-threonine kinase. Nature. 1999;401:82-85.
136. Remashkova JA, Makarov SS. NF-κB is a target of AKT in anti-apoptotic PDGF signalling. Nature. 1999;401:86-89.
137. Wu M, Lee H, Bellas RE, et al. Inhibition of NF-κB/Rel induces apoptosis of murine B cells. EMBO J. 1996;15:4682-4690.
138. Bargou RC, Emmerich F, Krappmann D, et al. Constitutive nuclear factor-κB-RelA activation is required for proliferation and survival of Hodgkin's disease tumor cells. J Clin Invest. 1997;100:2961-2969.
139. + bone marrow cell survival. Blood. 1999;93:3302-3308.
140. Beg AA, Baltimore D. An essential role for NF-κB in preventing TNF-α-induced cell death. Science. 1996;274:782-784.
141. Van Antwerp DJ, Martin SJ, Kafri T, Green DR, Verma IM. Suppression of TNF-α-induced apoptosis by NF-κB. Science. 1996;274:787-789.
142. Brockman JA, Scherer DC, McKinsey TA, et al. Coupling of a signal response domain in I kappa B alpha to multiple pathways for NF-kappa B activation. Mol Cell Biol. 1995;15:2809-2818.
143. Palombello V, Rando O, Goldberg A, Maniatis T. The ubiquitin-proteasome pathway is required for processing the NF-kappa B1 precursor protein and the activation of NF-kappa B. Cell. 1994;78:773-785.
144. Auphan N, DiDonato JA, Rosette C, Helmberg A, Karin M. Immunosuppression by glucocorticoids: inhibition of NF-κB activity through induction of IκB synthesis. Science. 1995;270:286-290.
145. Scheinman RI, Cogswell PC, Lofquist AK, Baldwin AS. Role of transcriptional activation of IkBa in mediation of immunosuppression by glucocorticoids. Science. 1995;270:283-286.
146. Wang CY, Cusack JC Jr, Liu R, Baldwin AS Jr. Control of inducible chemoresistance: enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-kappaB. Nat Med. 1999;5:412-417.
147. Diaz-Meco MT, Lallena M-J, Monjas A, Frutos S, Moscat J. Inactivation of the inhibitory κB protein kinase/nuclear factor κB pathway by Par-4 expression potentiates tumor necrosis factor α-induced apoptosis. J Biol Chem. 1999;274:19606-19612.
148. Friesen C, Herr I, Krammer PH, Debatin KM. Involvement of the CD95 (APO-1/FAS) receptor/ligand system in drug-induced apoptosis in leukemia cells. Nat Med. 1996;2:574-577.
149. Müller M, Strand S, Hug H, et al. Drug-induced apoptosis in hepatoma cells is mediated by the CD95 (APO-1/Fas) receptor/ligand system and involves activation of wild-type p53. J Clin Invest. 1997;99:403-413.
150. Fulda S, Sieverts H, Friesen C, Herr I, Debatin KM. The CD95 (APO-1/Fas) system mediates drug-induced apoptosis in neuroblastoma cells. Cancer Res. 1997;57:3823-3829.
151. Herr I, Wilhelm D, Bohler T, Angel P, Debatin KM. Activation of CD95 (APO-1/Fas) signaling by ceramide mediates cancer therapy-induced apoptosis. EMBO J. 1997;16:6200-6208.
152. Eischen CM, Kottke TJ, Martins LM, et al. Comparison of apoptosis in wild-type and Fas-resistant cells: chemotherapy-induced apoptosis is not dependent on Fas/Fas ligand interactions. Blood. 1997;90:935-943.
153. Villunger A, Egle A, Kos M, et al. Drug-induced apoptosis is associated with enhanced Fas (APO-1/CD95) ligand expression but occurs independently of Fas (APO-1/CD95) signaling in human T-acute lymphatic leukemia cells. Cancer Res. 1997;57:3331-3334.
154. Wesselborg S, Engels IH, Rossmann E, Los M, Schulze-Osthoff K. Anticancer drugs induce caspase-8/FLICE activation and apoptosis in the absence of CD95 receptor/ligand interaction. Blood. 1999;93:3053-3063.
155. Micheau O, Solary E, Hammann A, Dimanche-Boitrel M-T. Fas ligand-independent, FADD-mediated activation of the Fas death pathway by anticancer drugs. J Biol Chem. 1999;274:7987-7992.
156. Rehemtulla A, Hamilton CA, Chinnaiyan AM, Dixit VM. Ultraviolet radiation-induced apoptosis is mediated by activation of CD-95 (Fas/APO-1). J Biol Chem. 1997;272:25783-25786.
157. Aragane Y, Kulms D, Metze D, et al. Ultraviolet light induces apoptosis via direct activation of CD95 (Fas/APO-1) independently of its ligand CD95L. J Cell Biol. 1998;140:171-182.
158. Belka C, Marini P, Lepple-Wienhues A, et al. The tyrosine kinase Lck is required for CD95-independent caspase-8 activation and apoptosis in response to ionizing radiation. Oncogene. 1999;18:4983-4992.
159. Muzio M, Chinnaiyan AM, Kischkel FC, et al. FLICE, a novel FADD-homologous ICE/CED-3-like protease, is recruited to the CD95(Fas/Apo-1) death-inducing signaling complex. Cell. 1996;85:817-827.
160. Kataoka T, Schroter M, Hahne M, et al. FLIP prevents apoptosis induced by death receptors but not by perforin/granzyme B, chemotherapeutic drugs, and gamma irradiation. J Immunol. 1998;161:3936-3942.
161. Los M, Herr I, Friesen C, Fulda S, Schulze-Osthoff K, Debatin KM. Cross-resistance of CD95 and drug-induced apoptosis as a consequence of deficient activation of caspases (ICE/Ced-3 proteases). Blood. 1997;90:3118-3129.
162. Dbaibo GS, Perry DK, Gamard CJ, et al. Cytokine response modifier A (CrmA) inhibits ceramide formation in response to tumor necrosis factor (TNF)-α: CrmA and Bcl-2 target distinct components in the apoptotic pathway. J Exp Med. 1997;185:481-490.
163. Tepper AD, de Vries E, van Blitterswijk WJ, Borst J. Ordering of ceramide formation, caspase activation, and mitochondrial charges during CD95 and DNA damage-induced apoptosis. J Clin Invest. 1999;103:971-978.
164. Zeytun A, Hassuneh M, Nagarkatti M, Nagarkatti PS. Fas-Fas ligand-based interactions between tumor cells and tumor-specific cytotoxic T lymphocytes: a lethal two-way street. Blood. 1997;90:1952-1959.
165. Strand S, Hofmann WJ, Hug H, et al. Lymphocyte apoptosis induced by CD95 (APO-I/Fas) ligand-expressing tumor cells-a mechanism of immune evasion? Nat Med. 1996;2:1361-1366.
166. Schmidt-Wolf IG, Lefterova P, Johnston V, et al. Sensitivity of multidrug-resistant tumor cell lines to immunologic effector cells. Cell Immunol. 1996;169:85-90.
167. Frost P, Ng CP, Belldegrun A, Bonavida B. Immunosensitisation of prostate carcinoma cell lines for lymphocytes (CTL, TIL, LAK)-mediated apoptosis via the Fas-Fas-ligand pathway of cytotoxicity. Cell Immunol. 1997;180:70-83.
168. Micheau O, Solary E, Hammann A, Martin F, Dimanche-Boitrel M-T. Sensitization of cancer cells treated with cytotoxic drugs to Fas-mediated cytotoxicity. J Natl Cancer Inst. 1997;89:783-789.
169. Classen CF, Fulda S, Friesen C, Debatin KM. Decreased sensitivity of drug-resistant cells towards T cell cytotoxicity. Leukemia. 1999;13:410-418.
170. Cai Z, Stancou R, Körner M, Chouaib S. Impairment of Fas-antigen expression in adriamycin-resistant but not TNF-resistant MCF-7 tumor cells. Int J Cancer. 1996;68:535-546.
171. Landowski TH, Gleason-Guzman MC, Dalton W. Selection for drug resistance results in resistance to Fas-mediated apoptosis. Blood. 1997;89:1854-1861.
172. Barcena A, Park SW, Banapour B, Muench MO, Mechetner E. Expression of Fas/CD95 and Bcl-2 by primitive hematopoietic progenitors freshly isolated from human fetal liver. Blood. 1996;88:2013-2025.
173. Dirks W, Schöne S, Uphoff C, Quentmeier H, Pradella S, Drexler HG. Expression and function of CD95 (FAS/apo-1) in leukemia-lymphoma tumour lines. Br J Haematol. 1997;96:584-593.
174. Iijima N, Miyamura K, Itou T, Tanimoto M, Sobue R, Saito H. Functional expression of Fas (CD95) in acute myeloid leukemia cells in the context of CD34 and CD38 expression: possible correlation with sensitivity to chemotherapy. Blood. 1997;90:4901-4909.
175. Wen J, Ramadevi N, Nguyen D, Perkins C, Worthington E, Bhalla K. Antileukemic drugs increase death receptor 5 levels and enhance Apo-2L-induced apoptosis of human acute leukemia cells. Blood. 2000;96:3900-3906.
176. Sheikh MS, Burns TF, Huang Y, et al. p53-dependent and -independent regulation of the death receptor killer/DR5 gene expression in response to genotoxic stress and tumor necrosis factor alpha. Cancer Res. 1998;58:1593-1598.
177. Tishler RB, Calderwood SK, Coleman N, Price BD. Increase in sequence specific DNA binding by p53 following treatment with chemotherapeutic and DNA damaging agents. Cancer Res. 1993;53:2212-2216.
178. Lowe SW, Bodis S, McClatchey A, et al. p53 status and the efficacy of cancer therapy in vivo. Science. 1994;266:807-810.
179. Lowe SW, Ruley HE, Jacks T, Housman DE. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell. 1993;74:957-967.
180. Brown JM, Wouters BG. Apoptosis, p53, and tumor cell sensitivity to anticancer agents. Cancer Res. 1999;59:1391-1399.
181. Wattel E, Preudhomme C, Hecquet B, et al. p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies. Blood. 1994;84:3148-3157.
182. Navaratnam S, Williams GJ, Rubinger M, et al. Expression of p53 predicts treatment failure in aggressive non-Hodgkin's lymphomas. Leuk Lymphoma. 1998;29:139-144.
183. Han J-W, Dionne CA, Kedersha NL, Goldmacher VS. p53 status affects the rate of the onset but not the overall extent of doxorubicin-induced cell death in Rat-1 fibroblasts constitutively expressing c-Myc. Cancer Res. 1997;57:176-182.
184. El-Deiry WS, Tokino T, Velculescu VE, et al. WAF1, a potential mediator of p53 tumor suppression. Cell. 1993;75:817-825.
185. Vikhanskaya F, D'Incalci M, Broggini M. Decreased cytotoxic effects of doxorubicin in a human ovarian cancer-cell line expressing wild-type p53 and WAF1/CIP1 genes. Int J Cancer. 1995;61:397-401.
186. Gartenhaus RB, Wang P, Hoffmann P. Induction of the WAF1/CIP1 protein and apoptosis in human T-cell leukemia virus type I-transformed lymphocytes after treatment with adriamycin by using a p53-independent pathway. Proc Natl Acad Sci U S A. 1996;93:265-268.
187. Zhang W, Kornblau SM, Kobayashi T, Gambel A, Claxton D, Deisseroth AB. High levels of constitutive WAF1/Cip1 protein are associated with chemoresistance in acute myelogenous leukemia. Clin Cancer Res. 1995;1:1051-1057.
188. 1 activity induced by doxorubicin in synchronized P388 cells. Mol Pharmacol. 1996;49:832-841.
189. Kharbanda S, Yuan ZM, Rubin E, Weichselbaum R, Kufe D. Activation of Src-like p56/p53-yn tyrosine kinase by ionizing radiation. J Biol Chem. 1994;269:20739-20743.
190. Kharbanda S, Yuan ZM, Taneja N, Weichselbaum R, Kufe D. p56/p53-yn tyrosine kinase activation in mammalian cells treated with mitomycin C. Oncogene. 1994;9:3005-3011.
191. Giancotti FG, Ruoslahti E. Integrin signaling. Science. 1999;285:1028-1032.
192. Sethi T, Rintou RC, Moore SM, et al. Extracellular matrix proteins protect small cell lung cancer cells against apoptosis: a mechanism for small cell lung cancer growth and drug resistance in vivo. Nat Med. 1999;5:662-668.
193. Damiano JS, Cress AE, Hazlehurst LA, Shtil AA, Dalton WS. Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines. Blood. 1999;93:1658-1667.
194. Verfaillie CM. Adhesion receptors as regulators of the hematopoietic process. Blood. 1998;92:2609-2612.
195. Chen JJW, Wu R, Yang PC, et al. Profiling expression patterns and isolating differentially expressed genes by cDNA microarray system with colorimetry detection. Genomics. 1998;51:313-324.
196. Kudoh K, Ramana M, Ravata R, et al. Monitoring the expression profiles of doxorubicin-induced and doxorubicin-resistant cancer cells by cDNA microarray. Cancer Res. 2000;60:4161-4166.
197. Hannun YA. Apoptosis and the dilemma of cancer chemotherapy. Blood. 1997;89:1845-1853.